WARF Compound 42  

(Other name for: warfarin)

warfarin  

A synthetic anticoagulant. Warfarin appears to inhibit the regeneration of vitamin K1 epoxide and so the synthesis of vitamin K dependent clotting factors, which include Factors II, VII, IX and X, and the anticoagulant proteins C and S. This inhibition results in a sequential depression of Factors VII, IX, X and II activities. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K dependent clotting factors. The vitamin promotes the biosynthesis of gamma-carboxyglutamic acid residues in these proteins which are essential for biological activity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

water-based vaginal lubricant  

A water-based vaginal lubricant with hydration activity. Upon application to the vagina, the water-based vaginal lubricant provides moisture and may relieve dryness and sexual discomfort. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

WEE1 inhibitor MK-1775  

A small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. MK-1775 selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. Unlike normal cells, most p53-deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53-deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Wellbutrin  

(Other name for: bupropion hydrochloride)

Wellcovorin  

(Other name for: leucovorin calcium)

white button mushroom extract  

A heat-stable extract of white button mushrooms (Agaricus bisporus) with potential chemopreventive and immunomodulating activities. Phytochemicals, such as polysaccharides and especially beta-D-glucans found in the white button mushroom extract, bind to and inhibit the activity of aromatase, an enzyme responsible for the conversion of androgens to estrogens and which is often upregulated in breast cancer cells. The consequent decrease in estrogen production may result in the suppression of estrogen-dependent cellular proliferation. In addition, this extract may promote dendritic cell (DC) maturation, increase interferon gamma (IFN-gamma) and tumor necrosis factor alpha (TNF-alpha) production, and may enhance natural killer (NK) cell activity, thus amplifying both innate and T cell-mediated immune responses against cancer cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

white wine  

An alcoholic beverage made from fermented white grapes with potential orexigenic activity. Although not well understood, the mechanism for white wine's potential orexigenic activity may be due, in part, to its alcohol content and may involve alterations in neurotransmitter and hormone activities related to appetite regulation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

wild-type reovirus  

A serotype 3 Dearing strain (T3D) of reovirus (Respiratory Enteric Orphan virus) with potential oncolytic activity. Reovirus, a dsRNA virus, is able to replicate specifically in cancer cells bearing an activated Ras pathway. In contrast to normal cells, two-thirds of human cancer cells are Ras-activated. Unlike normal cells, Ras-activated tumor cells are deficient in host cellular protein kinase R (PKR) activity and so are unable to mount an antiviral response. In Ras-activated tumor cells, reovirus freely replicates and induces apoptosis; tumor cell lysis frees progeny viral particles to infect surrounding tumor cells. A cycle of infection, replication and cell death may continue until Ras-activated tumor cells are eradicated. PKR (eukaryotic translation initiation factor 2-alpha kinase 2) is activated by viral synthesis of double-stranded RNA and is an important component of innate immunity in vertebrates, protecting against viral infection. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Winobanin  

(Other name for: danazol)

WinRho SDF  

(Other name for: therapeutic immune globulin)

WT-1 analog peptide vaccine  

A peptide vaccine containing a human Wilms tumor 1 (WT-1) protein-derived epitope with potential antineoplastic activity. Vaccination with the WT-1 analog peptide vaccine may induce a cytotoxic T-lymphocyte (CTL) response against WT-1 expressing cells, resulting in tumor cell lysis and inhibition of tumor cell proliferation. WT-1, a zinc finger transcription factor, is overexpressed in most types of leukemia and in some solid cancers. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

WT1 126-134 peptide vaccine  

A synthetic peptide vaccine consisting of the amino acids 126 through 134 of the human Wilms' Tumor protein-1 (WT1) with potential antitumor activity. WT1, a tumor associated antigen, is overexpressed in most types of leukemia and in a variety of solid cancers. Vaccination with WT1 126-134 peptide vaccine may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

WT1 mRNA-electroporated autologous dendritic cell vaccine  

A cancer vaccine containing autologous dendritic cells electroporated with full-length mRNA encoding Wilms' tumor 1 (WT1) antigen with potential immunostimulatory and antineoplastic activities. Upon administration, WT1 mRNA-electroporated autologous dendritic cell vaccine may elicit a cytotoxic T-cell (CTL) response against tumor cells expressing WT1. Wt1 is frequently overexpressed in a variety of tumor cell types and often correlates with disease progression and poor prognosis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

WT1 peptide vaccine WT2725  

A peptide cancer vaccine comprised of a peptide derived from Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon administration, WT2725 may induce a specific cytotoxic T-lymphocyte (CTL) response against WT1-overexpressing tumor cells. WT1 protein, a zinc finger DNA-binding protein, is overexpressed in leukemic cells and in a vast number of non-hematological solid tumors. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

WT1-A10/AS01B immunotherapeutic GSK2130579A  

An immunotherapeutic consisting of the recombinant fusion protein WT1-A10 combined with the adjuvant ASO1B with potential immunostimulating and antineoplastic activities. Upon administration, WT1-A10/AS01B immunotherapeutic GSK2130579AWT1 may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells, resulting in cell lysis and the inhibition of cellular proliferation. The tumor-associated antigen WT1 (Wilms tumor protein-1) is overexpressed in most types of leukemia and in a variety of solid cancers. WT1-A10 is a 292 amino acid recombinant fusion protein consisting of a 12-mer truncated tat sequence (leader sequence) and amino acids number 2-281 of the WT1 sequence; ASO1B consists of a combination of the adjuvants monophosporyl lipd A (MPL) and Q21. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

WT1-sensitized T cells  

A population of allogeneic T-cells sensitized with Wilms tumor 1 (WT1) antigen with potential immunostimulatory and antineoplastic activities. Upon administration, WT1-sensitized T cells may bind to and lyse WT1-expressing tumor cells. WT1 antigen, a zinc finger DNA-binding protein acting as a transcriptional activator or repressor depending on the cellular or chromosomal context, is overexpressed in leukemic cells and in a vast number of nonhematological solid tumors. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Wymox  

(Other name for: amoxicillin)

Back to Top